Skip to content

Study · Animal study (in vivo) · rat · 1995

2 results

Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid.

Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL

Endocrinology1 Mar 1995Cited by 106 (Europe PMC)

PMID7867584 (opens in a new tab)DOI10.1210/endo.136.3.7867584 (opens in a new tab)PepBankPUB-07867584
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In female rats without estradiol, des(1‑3) IGF-I had a small but significant effect on mammary development.

    In plain wordsIn rats without estradiol, des(1‑3) IGF-I increased mammary development compared with control pellets.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMammary development without estradiol
    Study

    ratn: not reported in source

    Immature hypophysectomized oophorectomized female rats
    Comparator
    BSA-containing pellets
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · Local mammary gland implant · 5 daysAs given in this study (rat).

    Source sentences

    Summary
    In the absence of E2, des(1-3) IGF-I had a small, but significant, independent effect on mammary development; native IGF-I was ineffective.
    2 context sentences
    Summary · context
    Elvax pellets containing IGF-I or des(1-3) IGF-I were implanted into right lumbar mammary glands of sexually immature, hypophysectomized, oophorectomized female rats, with control BSA-containing pellets in the contralateral glands.
    Summary · context
    After 5 days, both lumbar mammary glands were removed and examined in whole mounts for mammary development by counting terminal end buds and alveolar structures.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 02AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome

    In female rats, adding estradiol to des(1‑3) IGF-I significantly enhanced mammary development compared with des(1‑3) IGF-I alone.

    In plain wordsIn rats, estradiol plus des(1‑3) IGF-I increased mammary development more than des(1‑3) IGF-I alone.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMammary development with estradiol
    Study

    ratn: not reported in source

    Immature hypophysectomized oophorectomized female rats
    Comparator
    des(1-3) IGF-I without estradiol
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    The addition of E2 significantly enhanced the effects of IGF-I and des(1-3) IGF-I on mammary development, similar to that noted when E2 was given along with GH.
    3 context sentences
    Summary · context
    In the absence of E2, des(1-3) IGF-I had a small, but significant, independent effect on mammary development; native IGF-I was ineffective.
    Summary · context
    Elvax pellets containing IGF-I or des(1-3) IGF-I were implanted into right lumbar mammary glands of sexually immature, hypophysectomized, oophorectomized female rats, with control BSA-containing pellets in the contralateral glands.
    Summary · context
    After 5 days, both lumbar mammary glands were removed and examined in whole mounts for mammary development by counting terminal end buds and alveolar structures.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.